iMBIORAY key facts
- Developer of innovative drugs intended for the treatment of tumors and immune diseases.
- It has raised $90.9M; the latest was Later Stage VC ($28.7M) in Feb 2026.
- Notable investors include Lapam Capital, Tailong VC, South China Venture Capital, Hangzhou Hi-Tech Financial Investment Group, Huayi Capital — 15 tracked in total.
- Status: Privately Held (backing).
Who backs iMBIORAY
15+Membership and data by Private Market View
- ·The complete investor list: 15 names
- ·Watch iMBIORAY: the Monday email on marks, rounds and moves
iMBIORAY funding rounds
No funding rounds for iMBIORAY are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
iMBIORAY investors
15 investors are on record for iMBIORAY, including Lapam Capital, Tailong VC, South China Venture Capital and Hangzhou Hi-Tech Financial Investment Group.
About iMBIORAY
Developer of innovative drugs intended for the treatment of tumors and immune diseases. The company offers research and clinical development programs focused on off-the-shelf natural killer cell therapies, with a drug focus on technology in non-genetically modified CAR-NK (Chimeric antigen receptor-NK) and Bispecific monoclonal antibody, providing enabling oncology and immunology clinicians, research hospitals, and biopharma cancer patients with advanced and targeted treatment.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2014
- Website
- imbioray.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
iMBIORAY doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.